OPKO Health's ModeX Therapeutics Initiates BARDA-Funded Phase 1 Trial for COVID-19 Prevention
OPK is trading near its 52-week low of $1.095 (9.6% above the low).
Summary
OPKO Health's subsidiary, ModeX Therapeutics, has initiated a Phase 1 clinical trial for MDX2301, a first-in-class multispecific antibody aimed at preventing COVID-19. This development is a positive step for the company's pipeline, especially as the trial is funded by the U.S. Department of Health and Human Services (BARDA), which significantly de-risks the early-stage development costs. The initiation of a new clinical program, particularly one with external funding, is a material event for OPKO, which recently reported a widened net loss and revenue decline for 2025. MDX2301 is designed to neutralize all known SARS-CoV-2 variants, offering potential broad and durable protection. Investors will closely watch for initial safety and tolerability data from this 80-participant study.
At the time of this announcement, OPK was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $888.1M. The 52-week trading range was $1.10 to $1.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.